High Uptake of Respiratory Syncitial Virus Prevention for Neonates in a Military Treatment Facility

Richelle L Homo, Andrew Groberg, Megan Donahue, Dustin Halverson, Anna Wooten, Adharsh Ponnapakkam

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

We investigated the uptake of nirsevimab for infants and the bivalent respiratory syncytial virus prefusion F (RSVPreF) vaccine for pregnant persons as measures for RSV prevention during an infant's birth hospitalization in a military treatment facility. We found >85% uptake between October 2023 to February 2024. These data may aid health systems plan for future RSV seasons.

Original languageEnglish
Pages (from-to)114144
JournalJournal of Pediatrics
Volume273
DOIs
StatePublished - Oct 2024
Externally publishedYes

Keywords

  • Humans
  • Infant, Newborn
  • Respiratory Syncytial Virus Infections/prevention & control
  • Female
  • Pregnancy
  • Respiratory Syncytial Virus Vaccines
  • Antibodies, Monoclonal, Humanized/therapeutic use
  • Antiviral Agents/therapeutic use
  • Military Personnel
  • Male
  • Hospitalization/statistics & numerical data

Cite this